Loading
Colorectal Cancer Treatments and Studies / Skin Diseases and Diabetes · Journal article
Clinical and Experimental Dermatology · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This case report describes spontaneous regression of approximately 40 eruptive melanocytic naevi in a single patient following cessation of the BRAF inhibitor encorafenib, with near-complete involution within 12 months confirmed by photography and histopathology. The observation supports the hypothesis that paradoxical MAPK pathway activation underlies BRAF inhibitor-associated eruptive naevi but cannot establish causality or generalizability without further evidence.
Single case report. One patient with BRAFV600E-mutated metastatic colorectal cancer treated with the BRAF inhibitor encorafenib. Intervention: Cessation of encorafenib (BRAF inhibitor). n = 1.
Patient developed approximately 40 widespread naevi within 2 months of starting encorafenib Near-complete involution of naevi occurred within 12 months of drug withdrawal Regression confirmed by serial full-body photographic mapping and histopathology
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case suggests that dermatological surveillance is warranted in patients receiving BRAF-targeted therapies and that eruptive naevi may regress upon drug cessation, but individual case reports cannot guide clinical practice without supporting evidence from larger studies.
A single case report documenting an observed phenomenon without experimental controls or comparison, providing descriptive evidence that warrants further investigation.
As stated by the source record.
Quoted from the source exactly as published.
This case suggests that dermatological surveillance is warranted in patients receiving BRAF-targeted therapies and that eruptive naevi may regress upon drug cessation, but individual case reports cannot guide clinical practice without supporting evidence from larger studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
We report the first case of spontaneous regression of eruptive melanocytic naevi (EMN) following cessation of encorafenib, a BRAF inhibitor, in a patient treated for BRAFV600E-mutated metastatic colorectal cancer. The patient developed approximately 40 widespread naevi within two months of starting treatment, which showed near-complete involution within 12 months of drug withdrawal, confirmed on serial full-body photographic mapping and histopathology. This case supports the proposed mechanism of paradoxical MAPK pathway activation as the driver of BRAFi-associated EMN, and highlights the importance of dermatological surveillance in patients receiving BRAF-targeted therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.